Assembly Biosciences Q3 net loss $23.1M; CEO retirement, new pipeline programs announced

ASSEMBLY BIOSCIENCES, INC.

2022-Q3 EPS reported -$1.46

Net loss of $23.1M ($0.48 per share) vs $18.8M ($0.41) in Q3 2021.
Cash and marketable securities $108.7M; projected to fund operations into H1 2024.
R&D expenses $18.1M, down slightly from $18.5M YoY.
CEO John McHutchison to retire end of 2022; President Jason Okazaki named successor.
Phase 1a trial of next-gen core inhibitor ABI-4334 initiated; new HSV-2 and herpesvirus programs introduced.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ASSEMBLY BIOSCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income Net loss attributable to common stockholders was $23.1 million, or $0.48 per basic and diluted share, EPS $0.48 per basic and diluted share.

Period: the third quarter ended September 30, 2022
Net income: Net loss attributable to common stockholders was $23.1 million, or $0.48 per basic and diluted share
EPS: $0.48 per basic and diluted share
Result: reported results

Exact text from the filing

Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-023218

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.